By Duke Medicine News and Communications Contact: Samiha Khanna Phone: 919-419-5069 Email: samiha.khanna@duke.edu https://www.dukehealth.org EMBARGOED FOR RELEASE until 12 p.m. (ET) on Thursday, July 14, 2016 DURHAM, N.C. — Scientists at Duke Health are part of a team that has discovered a type of cell surrounding blood vessels can also serve as a starting point for sarcoma, a Read more about Benjamin Alman, M.D., and Team Trace Origin Cell of Bone and Soft Tissue Tumors, Test Drug Target[…]

TORONTO (February 16, 2016) — ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes. This Read more about ScarX Therapeutics closes $2 million Series A financing[…]

Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in Read more about Gene mutation drives cartilage tumor formation[…]

Why do vampires from Dracula to Angel seem to crave the blood of the young and beautiful? The undead may be onto something. Young blood, it seems, has special healing properties that have been lost in older blood. A recent finding by scientists from the Hospital for Sick Children, Toronto, and Duke University challenges long-held ideas about Read more about Vampire Healing: Young Blood Can Mend Old Broken Bones[…]